RBOT · Vicarious Surgical Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $7.99M | $9.05M | $9.41M | - | $10.80M | $10.92M | $9.97M | - | $13.04M |
| SG&A | - | $3.16M | $4.12M | $5.29M | - | $5.75M | $5.59M | $5.00M | - | $6.91M |
| Total Operating Expenses | - | $11.50M | $13.52M | $15.75M | - | $17.75M | $17.71M | $16.11M | - | $21.35M |
| D&A | - | $352.0K | $413.0K | $369.0K | - | - | - | $521.0K | - | $338.0K |
| Operating Income | - | ($11.50M) | ($13.52M) | ($15.75M) | - | ($17.75M) | ($17.71M) | ($16.11M) | - | ($21.35M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | $1.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | ($11.06M) | ($13.21M) | ($15.39M) | - | ($17.09M) | ($15.21M) | ($17.00M) | - | ($15.70M) |
| EPS - Basic | - | - | - | - | - | - | ($2.59) | ($3.00) | - | ($3.00) |
| EPS - Diluted | - | - | - | - | - | - | ($2.59) | ($3.00) | - | ($3.00) |
Balance Sheet
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.57M | $3.16M | $3.91M | $2.60M | $9.74M | $7.07M | $20.25M | $38.22M | $52.82M | $59.11M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $894.0K | $915.0K | $721.0K | $1.02M | $1.17M | $2.42M | $1.35M | $1.27M | $1.26M | $1.53M |
| Current Assets | $11.58M | $15.07M | $26.07M | $39.65M | $51.70M | $63.98M | $75.93M | $87.11M | $100.95M | $113.41M |
| Total Assets | $19.58M | $29.35M | $40.89M | $55.05M | $67.72M | $80.62M | $93.35M | $105.29M | $119.86M | $132.05M |
| Current Liabilities | $3.90M | $3.18M | $5.10M | $7.86M | $7.67M | $8.60M | $7.18M | $5.08M | $7.28M | $7.80M |
| Long-term Debt | - | - | - | - | - | - | - | - | $2.00M | - |
| Total Liabilities | $9.74M | $15.26M | $17.83M | $20.98M | $21.02M | $22.73M | $21.49M | $21.28M | $21.89M | $24.18M |
| Stockholders' Equity | $9.84M | $14.09M | $23.06M | $34.08M | $46.70M | $57.88M | $71.86M | $84.01M | $97.97M | $107.87M |
| Retained Earnings | ($246.12M) | ($235.60M) | ($224.54M) | ($211.33M) | ($195.94M) | ($182.01M) | ($164.92M) | ($149.71M) | ($132.71M) | ($119.60M) |
Cash Flow
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($11.77M) | - | - | - | ($14.46M) | - | - |
| Investing Cash Flow | - | - | - | $4.61M | - | - | - | ($144.0K) | - | - |
| Financing Cash Flow | - | - | - | $17.0K | - | - | - | $2.0K | - | - |
| CapEx | - | - | - | $5.0K | - | - | - | $10.0K | - | - |
| Free Cash Flow | - | - | - | ($11.77M) | - | - | - | ($14.47M) | - | - |
Ratios
| Metric | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | 0.76 | - | - | - | 0.85 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -37.7% | -32.3% | -28.0% | - | -21.2% | -16.3% | -16.1% | - | -11.9% |
| Return on equity | - | -78.5% | -57.3% | -45.2% | - | -29.5% | -21.2% | -20.2% | - | -14.6% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.97 | 4.75 | 5.11 | 5.05 | 6.74 | 7.44 | 10.57 | 17.16 | 13.87 | 14.53 |
| Quick ratio | 2.97 | 4.75 | 5.11 | 5.05 | 6.74 | 7.44 | 10.57 | 17.16 | 13.87 | 14.53 |
| Cash ratio | 0.66 | 1.00 | 0.77 | 0.33 | 1.27 | 0.82 | 2.82 | 7.53 | 7.26 | 7.58 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | 0.02 | - |
| Debt / Assets | - | - | - | - | - | - | - | - | 0.02 | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | -21352.0x |
| Equity multiplier | 1.99 | 2.08 | 1.77 | 1.62 | 1.45 | 1.39 | 1.30 | 1.25 | 1.22 | 1.22 |
| Liabilities / Assets | 0.50 | 0.52 | 0.44 | 0.38 | 0.31 | 0.28 | 0.23 | 0.20 | 0.18 | 0.18 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | 2.3x | 1.9x | 1.1x | - | 0.6x | 0.5x | 18.9x | - | 25.5x |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 35.2% | 23.7% | 2.2% | - | 16.8% | 17.5% | 27.8% | - | 3.7% |
| Net income growth (YoY) | - | 35.3% | 13.1% | 9.5% | - | -8.8% | 0.8% | 36.9% | - | 65.2% |
| EPS growth (YoY) | - | - | - | - | - | - | -2058.3% | -1328.6% | - | -1400.0% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | 18.6% | - | - | - | 23.4% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -78.9% | -75.7% | -67.9% | -59.4% | -52.3% | -46.3% | -5.1% | -4.2% | -11.8% | -1.0% |
Peer comparison
Same SIC group: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Comparing Vicarious Surgical Inc. against the 5 most active filers in the same SIC group.